Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will host a KOL webinar on DM199, its leading asset for Acute Ischemic Stroke (AIS) treatment, on March 19, 2021. Key opinion leaders Scott Kasner, M.D., and Paolo Madeddu, M.D., will discuss treatment gaps and DM199's potential benefits. Management will update on DM199, a synthetic form of human tissue kallikrein-1, which showed a statistically significant 86% reduction in severe recurrent strokes in a recent study. An IND application for a phase 2/3 study is planned for Q1 2021.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced its participation in three investor conferences in March 2021. The conferences include the 33rd Annual Roth Conference on March 15, where management will engage in a fireside chat and 1-on-1 meetings. The Oppenheimer’s 31st Annual Healthcare Conference is scheduled for March 16, featuring a corporate presentation and 1-on-1 meetings. Lastly, the Maxim’s Emerging Growth Conference will take place on March 17, also including a corporate presentation and 1-on-1 meetings.
DiaMedica Therapeutics (Nasdaq: DMAC) will release its Q4 2020 financial results after market close on March 10, 2021. A live conference call to discuss these results and a business update is scheduled for March 11, 2021, at 7:00 AM CT. Interested listeners can access the call via phone or a simultaneous webcast, and a playback will be available for 12 months. The conference ID for the call is 9297319. For more information, visit www.diamedica.com.
DiaMedica Therapeutics (Nasdaq: DMAC) has announced that Dr. Harry Alcorn, Chief Medical Officer, will present a research update on CKD DM199 at the 3rd Chronic Kidney Disease Drug Development summit on March 2, 2021, at 1:00 PM ET. The presentation will cover data from the CKD Phase 1b study and the design of the Phase II Redux study. The CKD3 summit is a key event for discussing innovative treatments for chronic kidney disease, bringing together industry leaders to evaluate current drug pipelines and emerging therapies.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is set to present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The conference will be held virtually, and the recorded presentation will be accessible on the company's website starting January 11. DiaMedica focuses on creating innovative treatments for chronic kidney diseases and neurological disorders. Investors can find more information about the presentation and the company on their official website.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that enrollment in the diabetic kidney disease cohort of its Phase 2 REDUX chronic kidney disease study is complete, with all participants now on treatment. Additionally, 50% enrollment has been achieved in the IgA Nephropathy and African Americans cohorts. This study aims to assess the safety and efficacy of DM199 in approximately 90 participants across three cohorts. Positive results from earlier studies have raised expectations for topline results, anticipated in Q2 2021.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has received regulatory feedback from the FDA regarding its product candidate DM199 for treating acute ischemic stroke (AIS). The FDA's written responses, following a Pre-IND meeting, support the proposed design of a Phase 2/3 adaptive trial with a primary endpoint based on the modified Rankin Scale at day 90. The trial aims to enroll 300-350 participants and assess DM199's safety and efficacy. DiaMedica plans to file an IND submission soon, addressing a significant treatment gap for AIS patients within a 24-hour window.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 32nd Annual Virtual Growth Conference. The chat is scheduled for November 23, 2020, at 10:00 AM ET and available until December 3, 2020. One-on-one meetings can be requested through Piper Sandler on December 1, 2020. A replay of the chat will be accessible via the Investors section of DiaMedica's website.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls and CFO Scott Kellen will participate in the Craig-Hallum Alpha Select Conference on November 17, 2020. The conference will be held virtually due to social distancing measures amid the Covid-19 pandemic. Interested institutional investors should coordinate with their Craig-Hallum representative to arrange meetings. DiaMedica is focused on developing innovative treatments for chronic kidney diseases and neurological disorders.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has provided a business update and financial results for Q3 2020. Enrollment continues in the Phase II REDUX trial for DM199, targeting chronic kidney disease (CKD), but faces challenges due to COVID-19. 49 subjects are enrolled, with expectations for rapid enrollment in Cohort III. The FDA accepted a Type B meeting request regarding DM199 for acute ischemic stroke. A $23 million public offering was completed, bolstering cash reserves to $30.6 million. R&D expenses increased to $2.2 million, while total other income decreased to $128,000.